providing end-to-end integrated professional services for new drug clinical trials

 

Category: *CRO

Exhibitor: SHANGHAI UNIONCLIN CO,. LTD.(UNIONCLIN)

Booth No: M1106

 

Characteristic

 

Shanghai UnionClin Co., Ltd (UnionClin), founded in 2017 and headquartered in Shanghai, focuses on the fields of Oncology, Autoimmune, Infectious Diseases, Neurology, and Cardiovascular Diseases, providing end-to-end integrated professional services for new drug clinical trials, including strategy consulting, regulatory affairs, medical affairs, clinical operations, data management and statistics, clinical pharmacology, pharmacovigilance, IRC service, bioanalysis, site management, and FSP services.

UnionClin has established effective cooperative relationships with over 2,000 highly influential clinical experts and over 1000 research centers (including multiple national-level medical centers and clinical research entities such as the Department of Internal Medicine at Fudan University Shanghai Cancer Hospital, National Medical Center for Infectious Diseases, and National Medical Center for Cardiovascular Diseases) in the fields of oncology, autoimmune, infections, neurology, and cardiovascular diseases. Our clinical research network covers 28 provinces and municipalities and over 100 cities nationwide, which can quickly help clients match experts, centers, and patient pools.



Relying on network of clinical research centers and digital tools, we provide full-cycle solutions ranging from IND-NDA strategic consulting, IT research, Phase I to Phase III confirmatory studies. We have experience in dual filing experience in China and the U.S., innovative trial design, and global multi-center clinical research service capabilities; introducing high-quality overseas products to promote the internationalization of domestic innovative products.

UnionClin has 500 employees across over 100 cities nationwide. The core team members have over 15 years of industry experience on average and have provided services for over 400 clinical trials of innovative drugs.

 

 

 

Back